William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...
H.C. Wainwright launched coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $25 price target. The stock closed at $15.03 on April 26. Akouos is a precision genetic medicine company focused primarily on the...
BTIG initiated coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $35 price target. The stock closed at $21.12 on July 20. Akouos is focused on the development of highly specific genetic medicines for hearing loss...